ARCC-4

ARCC-4 is a low-nanomolar Androgen Receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy .


Cat. No.: EX-A8726	Purity: >98%

	Chemical structure of ARCC-4

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
500mg	get quote	In-stock
1g	get quote	In-stock
2g	get quote	In-stock
3g	get quote	In-stock
5g	get quote	In-stock
10g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1973403-00-7
Purity	>98%
Formula	C53H56F3N7O7S2
Mol Weight	1024.18
Color	yellow
State	solid powder
Solubility	DMSO: 200 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Salami J, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100.
CoA	CoA of ARCC-4

Smiles:	O=C(NCC1=CC=C(C2=C(C)N=CS2)C=C1)[C@H]3N(C([C@H](C(C)(C)C)NC(COCCCCOC4=CC=C(C5=CC=C(N(C(N6C7=CC=C(C#N)C(C(F)(F)F)=C7)=S)C(C)(C)C6=O)C=C5)C=C4)=O)=O)C[C@H](O)C3


		Search